Recently, immune checkpoint inhibitors against PD-1/PD-L1 or CTLA4 have emerged as new treatments for metastatic renal cell carcinoma (mRCC), despite discrepancy between their effects on OS and PFS. We performed a meta-analysis of randomized trials comparing immunotherapy to standard of care (SOC) in mRCC.
Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis
Iacovelli, Roberto;Ciccarese, Chiara;Bimbatti, Davide;Fantinel, Emanuela;Bisogno, Iolanda;Brunelli, Matteo;Tortora, Giampaolo;
2018-01-01
Abstract
Recently, immune checkpoint inhibitors against PD-1/PD-L1 or CTLA4 have emerged as new treatments for metastatic renal cell carcinoma (mRCC), despite discrepancy between their effects on OS and PFS. We performed a meta-analysis of randomized trials comparing immunotherapy to standard of care (SOC) in mRCC.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
